文献速递头颈与中枢神经肿瘤

Zotiraciclib(TG02)用于老年新诊断胶质母细胞瘤或复发胶质母细胞瘤:EORTC 1608 STEAM试验

Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
PubMed 文献 · Eur J Cancer · 2023-12-18

EORTC 1608(STEAM)为Ib期、开放标签、非随机、多中心三平行组研究,在IDH野生型新诊断胶质母细胞瘤或间变性星形细胞瘤中探索TG02的最大耐受剂量(A组联合单纯大分割放疗、B组联合单纯替莫唑胺)及复发时单药活性(C组)。最大耐受剂量为150 mg每周两次;C组6个月无进展生存率为6.7%;MCL-1高蛋白水平与更差生存相关。

要点

  • TG02最大耐受剂量为150 mg每周两次,联合单纯放疗(A组)或联合单纯替莫唑胺(B组)。
  • 150 mg剂量下观察到2例剂量限制性毒性:A组1例3级癫痫发作,B组1例多次1级事件。
  • C组(替莫唑胺放化疗后首次复发单药TG02)6个月无进展生存率为6.7%。

核心结论

  • TG02与烷化剂存在重叠毒性,在复发胶质母细胞瘤中单药临床活性低。
  • CDK-9及其下游效应因子作为胶质母细胞瘤预后因素和治疗靶点的作用需进一步研究。

研究设计与样本

  • EORTC 1608(NCT03224104)(STEAM)为Ib期、开放标签、非随机、多中心、三平行组(A、B、C)研究。
  • 研究对象为IDH野生型新诊断胶质母细胞瘤或间变性星形细胞瘤。
  • A组和B组在老年患者中探索TG02的最大耐受剂量,A组联合单纯大分割放疗,B组联合单纯替莫唑胺,根据中心检测的O6-甲基鸟嘌呤DNA甲基转移酶启动子甲基化状态分组。
  • C组探索替莫唑胺放化疗后首次复发时TG02单药活性,主要终点为6个月无进展生存率(PFS-6)。
  • 通过免疫组化检测肿瘤CDK-9、c-MYC和MCL-1表达。

主要发现

  • 最大耐受剂量为150 mg每周两次,联合单纯放疗(A组)或联合单纯替莫唑胺(B组)。
  • 150 mg剂量下观察到2例剂量限制性毒性:A组1例3级癫痫发作,B组1例多次1级事件。
  • 主要毒性包括中性粒细胞减少、胃肠道疾病和肝毒性。
  • C组6个月无进展生存率为6.7%。
  • CDK-9、c-MYC和MCL-1被证实表达,其表达呈中度交叉相关;MCL-1高蛋白水平与更差生存相关。

关键数值与推荐

  • 最大耐受剂量:150 mg每周两次(联合单纯放疗的A组或联合单纯替莫唑胺的B组)。
  • C组6个月无进展生存率:6.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Zotiraciclib (TG02) is an oral multi-cyclin dependent kinase (CDK) inhibitor thought to inhibit tumor growth via CDK-9-dependent depletion of survival proteins such as c-MYC and MCL-1 which are frequently overexpressed in glioblastoma. METHODS: EORTC 1608 (NCT03224104) (STEAM) had a three parallel group (A,B,C) phase Ib, open-label, non-randomized, multicenter design in IDH wild-type newly diagnosed glioblastoma or anaplastic astrocytoma. Groups A and B explored the maximum tolerated dose (MTD) of TG02 in elderly patients, in combination with hypofractionated radiotherapy alone (group A) or temozolomide alone (group B), according to O6-methylguanine DNA methyltransferase promoter methylation status determined centrally. Group C explored single agent activity of TG02 at first relapse after temozolomide chemoradiotherapy with a primary endpoint of progression-free survival at 6 months (PFS-6). Tumor expression of CDK-9, c-MYC and MCL-1 was determined by immunohistochemistry. RESULTS: The MTD was 150 mg twice weekly in combination with radiotherapy alone (group A) or temozolomide alone (group B). Two dose-limiting toxicities were observed at 150 mg: one in group A (grade 3 seizure), one in group B (multiple grade 1 events). Main toxicities included neutropenia, gastrointestinal disorders and hepatotoxicity. PFS-6 in group C was 6.7%. CDK-9, c-MYC and MCL-1 were confirmed to be expressed and their expression was moderately cross-correlated. High protein levels of MCL-1 were associated with inferior survival. CONCLUSIONS: TG02 exhibits overlapping toxicity with alkylating agents and low single agent clinical activity in recurrent glioblastoma. The role of CDK-9 and its down-stream effectors as prognostic factors and therapeutic targets in glioblastoma warrants further study.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Le Rhun E, Gorlia T, Felsberg J, et al. Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial. Eur J Cancer. 2023. PMID: 38159337. doi:10.1016/j.ejca.2023.113475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。